Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the update, animal study program EPIL-A21-1 was designed to determine whether DehydraTECH-CBD could provide similar seizure inhibiting efficacy, using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation (“MES”), at lower doses than were required with Epidiolex, the world’s only commercially approved, CBD-powered anti-seizure drug. In order to minimize adverse side effects, Lexaria is continually searching for the lowest possible efficacious dose levels of the drugs it formulates with DehydraTECH. An initial MES pilot study in animals examined three different doses and revealed that DehydraTECH-CBD was more efficacious than Epidiolex in reducing or eliminating seizure activity at the lower doses of 50 mg/kg and 75 mg/kg. Epidiolex was more efficacious in eliminating seizure activity at the highest dose of 100 mg/kg tested in the pilot study. Only DehydraTECH-CBD demonstrated some reduction in seizure activity at the 50 mg/kg dose and, at the 75 mg/kg dose, DehydraTECH-CBD demonstrated full elimination of seizure activity in 66.6% of the animals compared to 50% of Epidiolex-treated animals.

Following the pilot experiment, a second MES animal seizure study was performed measuring time to peak efficacy at various post-dosing time points. In this case, based on rapidity of action, DehydraTECH-CBD also showed an apparent trend toward enhanced effectiveness. At the 30-minute timepoint, 50% of the animals dosed with DehydraTECH-CBD showed partial reduction or full elimination of seizure activity whereas 100% of the Epidiolex-dosed animals were exhibiting full seizure activity. At the 60-minute timepoint, 87.5% of DehydraTECH-CBD-dosed animals showed partial reduction or full elimination of seizure activity compared to 62.5% of the Epidiolex-dosed animals showing partial reduction or full elimination of seizure activity. Epidiolex showed some enhanced capabilities in seizure reduction at later time points in the study.

To view the full press release, visit https://ibn.fm/WCRxD

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness. Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive) treatment. Results of the trial will inform design of the first-in-human clinical trial of the inhaled NanoAb COVID-19 therapy, which is planned for late 2023,” said BiondVax’s Chief Science Officer Dr. Tamar Ben-Yedidia PhD. “On behalf of BiondVax’s team, I would like to thank the teams at Fraunhofer ITEM and TiHo for their professionalism in conducting this ongoing trial, and also our research partners Professor Dr. Dirk Görlich of the Max Planck Institute for Multidisciplinary Sciences (‘MPG’) and Professor Dr. Matthias Dobbelstein of the University Medical Center Göttingen and their teams for the ongoing collaboration.”

To view the full press release, visit https://ibn.fm/tIacr

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) Carries Out Exploratory Drilling Work at Iska Iska Project; Receives Mention by Brent Cook as Showing ‘Great Potential’

  • Bolivia’s Potosi region has long been one of the world’s most prolific silver deposits, with continuous mining operations taking place over the past 500 years
  • Eloro Resources possesses a 99% option agreement on the Iska Iska deposit, a major polymetallic epithermal porphyry complex covering over 900 hectares of land
  • Eloro Resources was recently highlighted by renowned mining analyst, Brent Cook during his appearance on the Wall Street Silver podcast
  • Eloro’s Iska Iska project was characterized as a polymetallic mining project possessing great potential due to its size as well as the mining team’s technical nous

The discovery of Bolivia’s Potosi silver mine in 1545 was a matter of chance. Don Diego Gualpa, an Andean man recounted the tale to the Spanish viceroy taking charge of the region whilst on his deathbed; Gualpa detailed how, whilst hiking on the mountain in search of a religious monument rumoured to be in the area, he was bowled over by a powerful gust of wind. Upon rising, he noticed that the dirt on his hands was rich in ore. The discovery of the Potosi mine was not the first silver mine found in the Americas, however it was by far the most prolific. During its most active period, Potosi produced almost half of the silver in circulation globally and ultimately accounted for nearly 20 percent of all ‘the known silver produced in the world across 265 years’ (https://ibn.fm/TCAUK). Today’s the Cerro Rico de Potosi remains a world-class silver and tin reserve despite being mined nearly continuously since the sixteenth century and producing a reported 2.5 billion ounces of silver since work first began.

Seeking to channel some of the success enjoyed by its illustrious neighbour, Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec has emerged as one of the most promising mining companies in the Americas, boasting access to one of the largest, undeveloped mining tracts within Bolivia’s Potosi region. Having signed a definitive option agreement on Iska Iska to acquire a 99% interest in the project, Eloro plans to undertake an exploration and development projected designed to verify the feasibility of extracting minerals from the territory.

 Eloro Resources’ potential has been increasingly commented on by the market and most recently by renowned mining analyst, Brent Cook. A seasoned geologist and independent exploration analyst with over 30 years of experience working across 60 countries and identifying economically viable mining deposits, Cook’s Exploration Insights newsletter has emerged as an industry standard within the mining community.

During a recent appearance on the Wall Street Silver podcast, Cook mentioned Eloro Resources as one of his top investment picks. As Cook described, the potential and likely size of Eloro’s Iska Iska polymetallic silver-tin mining project coupled with the company’s strong technical nous – lead geologist Quinton Hennigh boasts over 25 years of exploration experience across a wide array of mining companies – made it an appealing prospect for mining majors such as Pan American Silver Corp (NASDAQ: PAAS), a multi-billion dollar mining giant with operations in the project’s near vicinity (https://ibn.fm/squH9).

Eloro Resources revealed that exploration drilling at its Iska Iska project showed widespread mineralization. The company said best results from assays on holes on its lands included DSB -30: 441.21 meters of 150.47 grade gramAgEquivalent/ton (gAGEq/t) and DSBU-10: 349.03 meters of 188.64 grade gAGEq/t. Furthermore, the company stated that it currently had four exploration holes with a combined length of 6,000 meters being drilled at Iska Iska, with work expected to be complete by mid-November, while assays are awaited for 14,213 meters of core from prior work. Following the completion of the upcoming exploratory works, Eloro plans to publish an NI 43-101 inferred resource report or MRE, providing the market with further scientific and technical information about the economic viability of its project (https://ibn.fm/TEtTP).

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Eloro Resources Ltd. ELRRF | Leave a comment

MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Uncovering Potential for Iska Iska to Become ‘Bonanza Style’ Bolivian Polymetallic Discovery

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) today announced assay results from eight additional diamond drill holes from its ongoing drilling program at the Iska Iska silver-tin polymetallic project in the Potosi Department, southern Bolivia. According to the update, six of the holes (DSB-35 and DSB-37 to DSB-41) tested the south-southeastern extension of the high-grade feeder zone at Santa Barbara while METSBUG-03 is a metallurgical hole drilled from the Santa Barbara adit underground drill bay. DM2-01 is a reconnaissance drill hole near the Mina 2 adit in the southeast section of the property. “Now that the reconnaissance drill holes just released, DSB-38, -39 and -40, are adding a further 500 meters of mineralized strike length, these latest results should add substantial tonnage to our resource model. Infill drilling at a later date should further upgrade and expand the higher metal value zonations that have become characteristic of the Iska Iska system,” said Tom Larsen, CEO of Eloro. “Given the guidance of our geophysics, if one were to draw a line from Huayra Kasa in the north of the Iska Iska Caldera southwest to Mina Casiterita one can reasonably assume up to a 3 kilometre potential strike length of mineralization given the magnetic data to date. The current strike length, width and depth of the Santa Barbara complex, which is still open in all directions, is pointing to the strong possibility that Iska Iska will become a giant ‘bonanza style’ Bolivian polymetallic discovery.”

To view the full press release, visit https://ibn.fm/OFCmd

About Eloro Resources Ltd.

Eloro is an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Eloro has an option to acquire a 99% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department, in southern Bolivia. A recent NI 43-101 technical report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the north-central mineral belt of Peru some 50 km south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Eloro Resources Ltd. ELRRF | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

  • In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies
  • The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell
  • The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases – with a primary focus on diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma, and psoriasis.

The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies in collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), both in Germany. The NanoAb project’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was recently awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his seminal work describing protein transport within the cell (https://ibn.fm/vxCaD).

“I wish to offer my sincere congratulations to Dirk on being awarded the inaugural WLA Prize in Life Sciences. The award signals recognition and appreciation of his important research achievements and deep scientific acumen. His expertise extends to the unique and innovative NanoAb candidates being developed under our collaboration,” CEO Amir Reichman said, on behalf of the BiondVax team. “We look forward to forging ahead together with Dirk, Matthias, and their teams as we strive to bring a pipeline of NanoAb therapies that exhibit significant competitive advantages for conditions underserved by currently approved therapeutics.”

BiondVax’s NanoAbs, also known as VHH-antibodies or nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production.

BiondVax currently has an exclusive worldwide license for the development and commercialization of an inhaled COVID-19 NanoAb therapy, expected to enter clinical trials in 2023. BiondVax, Max Planck, and UMG also signed a broad five-year research collaboration in March 2022 under which BiondVax has exclusive options for similar worldwide licenses for NanoAbs addressing large market disorders currently underserved by approved therapeutic antibodies.  The agreement covers the discovery, development, and commercialization of NanoAbs therapies for indications such as asthma, psoriasis, macular degeneration, and psoriatic arthritis.

The global market for autoimmune disorder therapies such as asthma, arthritis and psoriasis is expected to grow from $53.2 billion in 2019 to $90.7 billion by 2024, growing at a CAGR of 11.2% over the forecast period (https://ibn.fm/tTedJ). The global infectious disease therapeutics market is expected to grow from an estimated $119.87 billion in 2022 to $167 billion in 2030, growing at a CAGR of 4.23% (https://ibn.fm/DUAZ4). The primary factors driving key growth in these markets are the increased number of cases suffering from infectious and autoimmune diseases and the growing senior population.

The company is in a unique position to advance NanoAb innovation from R&D through commercialization and offers a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. Since being founded BiondVax has executed eight clinical trials including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate. The company built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities, and offices.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Leads the Way Towards a Renewable Energy-Powered Future Within Canada

  • The recent UN-sponsored COP27 Conference has highlighted the pressing need for significant climate-focused initiatives
  • A UN panel led by Canada’s former environment minister has pushed for an urgent shift away from fossil fuels and towards renewable energy sources
  • RNG platform operator, EverGen Infrastructure have been at the forefront of the renewable energy transformation taking place across both, the province of British Columbia and Canada as a whole
  • The company has recently stated its goal to expand its production capacity to 20 locations across the country by 2025

The United Nations Framework Convention on Climate Change – better known as COP27 – is taking place in Egypt’s Sharm el-Sheikh amidst one of the most significant climate emergencies ever experienced by man. A growing energy crisis, record greenhouse gas (“GHG”) concentrations, and ever-increasing extreme weather events have significantly augmented the need for a coordinated, proactive global effort to combat global warming. The world has responded to a degree; 1,156 publicly listed companies, regions and cities have made net-zero pledges so far. Whilst promising on paper, several pledges have been a little more than vague commitments or proposals with scarce detail on how they will be implemented or tracked. In response, a United Nations advisory panel, led by Canada’s former environment minister Catherine McKenna, has called upon governments around the world to impose on companies to make serious net-zero emissions targets whilst simultaneously enforcing compliance, in an effort to ensure targets to slash emissions are adhered to (https://ibn.fm/m1xgH).

In addition to the regulatory enforcement of net-zero targets, the UN panel offered recommendations on an array of other measures, including the phasing out of fossil fuels in conjunction with a fully funded shift to renewable energy sources, a change characterized as key towards the achievement of overarching climate goals.

Ms. McKenna elaborated on the recommendation, “They [energy companies] have the means and the scale to be able to do big things on the renewables side, but they’re not even investing in these technologies.”

British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) may be one of the outliers within McKenna’s assessment. The company ranks amongst the leaders in driving the ongoing shift towards renewable energy resources within Canada, having firmly established themselves as one of the leading renewable natural gas (“RNG”) infrastructure platforms within the country. EverGen has done so via an operating model focused around acquiring, developing, owning and operating RNG projects in a bid to supply the North American gas grid with clean energy generated from organic waste.

EverGen Infrastructure’s path to becoming one of Canada’s largest RNG platforms, owes its origins to the province of British Columbia’s decision in March 2017 to amend the Greenhouse Gas Reduction Regulation. The amendment, which sought to increase the production and use of renewable gas as well as green and waste hydrogen in British Columbia to simultaneously generate jobs and economic opportunities while reducing GHG emissions, has played a significant role in driving the sector’s growth prospects in recent years. FortisBC has since further reinforced the government ordinance, with the British Columbia-based utility recently revealing that it expects to more than triple its current RNG supply in the coming years. The utility has publicized their vision to have upwards of 75 percent of its total gas supply to be renewable or low carbon by 2050; in the interim, they expect to have 16 million gigajoules of RNG in its system, with contracts in place to procure a further 8 million gigajoules by 2025. Cumulatively, the utility’s RNG supply within the next three years will provide enough energy to meet the natural gas needs of approximately 267,000 homes within BC (https://ibn.fm/zaFDn).

EverGen Infrastructure have looked to cater to the ever-increasing RNG demand from FortisBC and other utilities across the nation through the company’s publicly stated goal to own over 20 facilities dotted round the country within five years. Most recently this October, the company announced that the expansion plans for its recently acquired GrowTEC business were nearing completion, with the works adding a further 60,000 gigajoules of RNG to their existing production capacity, taking total production capacity within the operation to 140,000 gigajoules per annum (https://ibn.fm/okc6o). The project will further bolster to EverGen’s existing production capacity, with the latter currently standing at over 230 gigajoules per day of renewable natural gas – the equivalent of powering 100 British Columbia homes for a month.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in EverGen Infrastructure Corp. EVGIF | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted basis a new CUSIP number: 18978H201. Approved by company stockholders earlier this year, the reverse stock split is meant to increase the CNSP’s per share trading price and bring the company into compliance with the NASDAQ’s minimum share price listing requirement. The company noted that “the reverse split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the company’s equity, except to the extent that the reverse split results in some stockholders owning a fractional share.”

To view the full press release, visit https://ibn.fm/FAJjQ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

  • Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications
  • Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after
  • These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks
  • There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes
  • The success of these two studies will draw Lexaria closer to tapping into the dementia drug market, which is projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027

Lexaria Bioscience (NASDAQ: LEXX) just announced two notable studies, DEM-A22-1, and DIAB-A22-1, on dementia and diabetes, respectively, scheduled for completion in January 2023. The studies seek a deeper understanding of the company’s patented DehydraTECH(TM)-processed CBD for its potential therapeutic utility against both conditions (https://ibn.fm/Uta3i).

According to John Docherty, Lexaria’s President and Head of Research, these studies will build on the just-concluded hypertension clinical study whose results he referred to as “truly exceptional.”  The study demonstrated a statistically significant lowering of blood pressure in the patient population over multiple weeks, something that, Docherty noted, other entities using other oral CBD formulations have failed to replicate or even evidence.

“The study demonstrated excellent safety and tolerability of DehydraTECH-CBD and no adverse changes in liver enzymes throughout the study, a common concern in CBD dosing. We were also able to show that decreases in blood pressure were similar in participants currently taking standard of care hypertension medications to those not undergoing any concurrent blood pressure treatment,” he noted.

There is an established link between hypertension and vascular dementia. In addition, hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes. Lexaria looks to draw from the success of its hypertension clinical study to show DehydraTECH-CBD’s potential to offer potential therapeutic utility against these two conditions.

Currently, dementia is ranked as the seventh leading cause of death among all diseases, accounting for 40 out of every 100,000 deaths in the United States (https://ibn.fm/V8TiC). It also currently affects seven million Americans and has a significant unmet need that Lexaria hopes to meet. Diabetes, on the other hand, ranks as the eighth leading cause of death in the United States, accounting for 31 out of every 100,000 deaths in the country (https://ibn.fm/ACcAT). Over 37.3 million people, representing 11.3% of the country’s population, live with the condition, yet few viable treatment options are available for them (https://ibn.fm/3O03G).

CBD has, so far, shown some ability to reduce the incidence of diabetes in mice due to its powerful anti-inflammatory and antioxidant properties. In addition, Lexaria has proven DehydraTECH’s ability to cross the blood-brain barrier effectively. As such, it is optimistic that it will achieve potential treatment for both dementia and diabetes.

“We are excited to investigate whether DehydraTECH-CBD has a potential application in the treatment of dementia and diabetes based on its propensity to cross the blood-brain barrier, the fact that DehydraTECH-CBD lowers human blood pressure, and the fact that CBD is known to have vasodilatory, anti-inflammatory and antioxidant effects,” noted Mr. Docherty.

The two studies will be undertaken by leading third-party testing laboratories in Canada, with analysis and reporting set to follow their scheduled completion in January 2023. Their success will draw Lexaria closer to tapping into the dementia drug market, projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss initiation of coverage of Aditxt with a buy rating and 12-month price target of $4 per share. “Personalized COVID-19 analytics can inform vaccinations, treatments and more. AditxtScore determines the coronavirus infection status of an individual, which can help patients and physicians make a variety of informed decisions around vaccinations, treatments and levels of immunity. For example, AditxtScore can help a patient determine if they should receive a COVID-19 vaccination booster shot. Alternatively, AditxtScore can help immunocompromised patients determine their current level of immunity after receiving vaccinations, which can help inform personal decisions, such as whether to refrain from travel,” the reports read. “Infection status is determined by evaluating the presence/absence of the virus and immunity status by measuring levels of neutralizing antibodies against viral antigens. As the coronavirus pandemic transitions to becoming endemic, we believe there will be a substantial need for technologies that help discern if and when a patient should receive additional booster shots, and we believe AditxtScore can help inform these decisions and lead to more effective prevention and management of COVID-19 infections.”

To view the full reports, visit https://ibn.fm/rWJvt and https://ibn.fm/j09Og

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Aditxt Inc. ADTX | Leave a comment

Correlate Infrastructure Partners Inc. (CIPI) Helps Clients Achieve ESG Goals Through Proprietary Analytics, Advisement

  • Corporations worldwide are working to improve their climate friendliness through a variety of environmental, social and governance (“ESG”) factors
  • U.S. distributed energy solutions innovator Correlate Infrastructure Partners Inc. is a company working strategically with clients to assess their energy emissions profile and identify possible improvements and funding opportunities for those improvements
  • CIPI’s advisement helps clients achieve transparency in their ESG responsibility and to make improvements in a cost-beneficial manner
  • CIPI has realized record revenues during the most recent quarter as a result of its operations and still has $16.2 million in unrecognized revenues anticipated from work currently under way

Environmental, social and governance (“ESG”) responsibility has come to define corporate attention to climate change and steady drive toward clean energy adoption. While nearly a decade has passed since some 200 international entities and their governments forged a compact for reducing fossil fuel dependence and analysts expect several more to pass before meaningful progress becomes apparent, improvements are under way (https://ibn.fm/Jt8QL).

One entity helping to advance progress on the greenhouse gas reduction front is a tech-enabled development, finance, and fulfillment platform from Correlate Infrastructure Partners (OTCQB: CIPI). The company is making it easier and cost effective for those in the commercial real estate industry to acquire the necessary solutions for solar, cogeneration, energy storage, and electric vehicle infrastructure, as well as driving intelligent efficiency retrofits for community-scale applications.

The key for companies to open the door to ESG success is to first evaluate their current energy use and emissions profile and identify key stakeholders who will be vital to advancing any strategy toward new targets. Correlate Infrastructure provides proprietary analytics and advisement for companies seeking to reduce the carbon footprint of their buildings before helping clients navigate the tricky journey toward managing and financing infrastructure improvements for a better and more affordable ESG outcome.

“Correlate Infrastructure Partners is making energy management and procurement transparent and cost-effective as we digitize the process that has been archaic for way too long,” CEO Todd Michaels stated earlier this year (https://ibn.fm/Rsdg7). “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets.”

To be effective in reducing their carbon emissions, companies need to consider not only the facilities they control directly, but also the impact of the utilities they purchase and other indirect expressions of their energy use profile upstream and downstream from their operations.

Once the elements of a reduced-emissions profile are identified and a strategy established, companies can begin working toward acquisition of necessary resources for on-site renewables or power purchase agreements as appropriate, reporting progress according to company standards and communicating that progress to the public.

Correlate’s ability to provide clients with distributed energy solutions that come with smart cost-reduction incentives and associated financing has led to record revenues for the most recently reported quarter. In addition, the company has another $16.2 million in unrecognized revenues anticipated from work that is currently under way. Overall, the company foresees project opportunities valued at up to $194 million.

For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Correlate Infrastructure Partners Inc. CIPI | Leave a comment